SkyePharma's DepoDur for pain approved by U.K. agency

By Lisa Kerner

Erie, Pa., April 28 - SkyePharma plc said the U.K. Medicines and Healthcare products Regulatory Agency has approved its DepoDur for the treatment of pain following surgery.

DepoDur (formerly DepoMorphine) is a novel single dose sustained-release injectable formulation of morphine.

The company said it expects additional approvals in other European markets under the Mutual Recognition Process.

SkyePharma's clinical trial program for DepoDur included more than 1,000 patients in four different pain models, according to a company news release.

DepoDur is licensed to Endo Pharmaceuticals for sale in the United States.

SkyePharma, based in San Diego, specializes in injectable pharmaceutical products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.